MaxCyte (MXCT) Financials: History & Chart

MaxCyte, Inc.(MXCT)

Biotechnology · Rockville, MD

$1.06-0.03 (-2.31%)

Delayed quote: Oct 6, 2026, 1:04 PM EDT

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Rockville, MD

91 employees

www.maxcyte.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Maher Masoud

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	31.05M	7.27M	9.65M	7.30M	6.83M	8.51M	10.39M	8.69M	8.16M
Cost of Goods Sold	6.39M	1.68M	2.58M	1.61M	516K	1.52M	1.50M	2.28M	1.93M
Gross Profit	24.66M	5.60M	7.07M	5.69M	6.31M	6.99M	8.89M	6.41M	6.24M
Gross Profit Margin	79.4%	77.0%	73.2%	77.9%	92.4%	82.1%	85.6%	73.8%	76.4%
Total Operating Expenses	59.33M	15.83M	13.25M	13.36M	16.89M	21.21M	21.19M	19.31M	20.29M
Research & Development	16.76M	4.25M	3.86M	3.33M	5.32M	6.27M	5.90M	4.61M	5.32M
Selling, General & Administrative	38.94M	10.62M	9.39M	8.99M	9.94M	13.87M	14.22M	13.68M	13.95M
Operating Income (EBIT)	-34.66M	-10.23M	-6.18M	-7.67M	-10.57M	-14.23M	-12.29M	-12.90M	-14.05M
Operating Margin	-111.6%	-140.7%	-64.1%	-105.1%	-154.8%	-167.2%	-118.3%	-148.4%	-172.1%
Income Before Tax (EBT)	-35.64M	-8.87M	-4.75M	-9.60M	-12.42M	-12.36M	-10.26M	-10.60M	-11.56M
Interest Income	6.16M	1.36M	1.44M	1.63M	1.73M	1.87M	2.03M	2.30M	2.50M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	-975K	1.36M	1.44M	-1.92M	-1.84M	1.87M	2.03M	2.30M	2.50M
Net Income	-35.64M	-8.87M	-4.75M	-9.60M	-12.42M	-12.36M	-10.26M	-10.60M	-11.56M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-114.8%	-122.0%	-49.2%	-131.5%	-181.8%	-145.3%	-98.8%	-121.9%	-141.6%
EBITDA	-30.27M	-9.03M	-5.14M	-6.38M	-9.72M	-12.93M	-11.02M	-11.37M	-12.99M
EBITDA Margin	-97.5%	-124.2%	-53.2%	-87.5%	-142.4%	-152.0%	-106.0%	-130.8%	-159.1%
Depreciation & Amortization	4.39M	1.21M	1.05M	1.29M	848K	1.30M	1.28M	1.53M	1.07M
EPS Basic	-0.33	-0.08	-0.04	-0.09	-0.12	-0.12	-0.10	-0.10	-0.11
EPS Diluted	-0.33	-0.08	-0.04	-0.09	-0.12	-0.12	-0.10	-0.10	-0.11
Weighted Average Basic Shares	106.82M	106.82M	106.88M	106.43M	106.32M	106.40M	105.95M	104.85M	105.11M
Weighted Average Diluted Shares	106.82M	106.82M	106.88M	106.43M	106.32M	106.40M	105.95M	104.85M	105.11M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	33.03M	38.63M	41.29M	44.26M	33.89M	26.17M	21.62M	16.67M
Cost of Goods Sold	6.22M	7.10M	4.74M	5.10M	3.65M	2.77M	2.50M	1.84M
Gross Profit	26.80M	31.53M	36.55M	39.16M	30.25M	23.40M	19.12M	14.83M
Gross Profit Margin	81.2%	81.6%	88.5%	88.5%	89.2%	89.4%	88.4%	89.0%
Total Operating Expenses	72.09M	82.72M	84.84M	66.52M	48.44M	34.46M	31.54M	23.25M
Research & Development	20.82M	22.23M	23.82M	19.51M	15.41M	17.73M	17.59M	11.24M
Selling, General & Administrative	47.04M	56.35M	57.04M	44.48M	31.68M	15.70M	13.41M	12.01M
Operating Income (EBIT)	-45.28M	-51.20M	-48.30M	-27.36M	-18.19M	-11.06M	-12.42M	-8.42M
Operating Margin	-137.1%	-132.5%	-117.0%	-61.8%	-53.7%	-42.3%	-57.4%	-50.5%
Income Before Tax (EBT)	-44.63M	-41.05M	-37.92M	-23.57M	-19.08M	-11.82M	-12.89M	-8.87M
Interest Income	7.27M	10.14M	10.38M	3.92M	151K	66K	206K	170K
Interest Expense	N/A	N/A	N/A	127K	1.04M	826K	681K	615K
Other Income/Expense	655K	10.14M	10.38M	3.79M	-894K	-760K	-475K	-444K
Net Income	-44.63M	-41.05M	-37.92M	-23.57M	-19.08M	-11.82M	-12.89M	-8.87M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-135.1%	-106.3%	-91.8%	-53.3%	-56.3%	-45.2%	-59.6%	-53.2%
EBITDA	-40.14M	-46.41M	-44.13M	-24.66M	-16.76M	-10.01M	-11.81M	-8.08M
EBITDA Margin	-121.5%	-120.1%	-106.9%	-55.7%	-49.5%	-38.2%	-54.6%	-48.5%
Depreciation & Amortization	5.14M	4.79M	4.17M	2.70M	1.42M	1.05M	614K	344K
EPS Basic	-0.42	-0.39	-0.37	-0.19	-0.22	-0.18	-0.24	-0.17
EPS Diluted	-0.42	-0.39	-0.37	-0.19	-0.22	-0.18	-0.24	-0.17
Weighted Average Basic Shares	106.43M	104.85M	103.27M	101.70M	90.62M	69.46M	56.40M	51.18M
Weighted Average Diluted Shares	106.43M	104.85M	103.27M	101.70M	90.62M	69.46M	56.40M	51.18M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.